Pfizer Inc.’s Price-to-Sales Ratio at a glance
Pfizer Inc. reports price-to-sales ratio of 2.4x for Dec 2024. The prior period recorded 2.7x (Dec 2023). Year over year the metric moved −0.37 (−13.4%). The rolling three-period average stands at 2.7x. Data last refreshed Dec 7, 2025, 2:50 AM.
Latest reading
2.4x · Dec 2024
YoY movement
−0.37 (−13.4%)
Rolling average
2.7x
Current Price-to-Sales Ratio
2.4x
−0.37
−13.4%
Rolling average
2.7x
Latest Value
2.4x
Dec 2024
YoY Change
−0.37
Absolute
YoY Change %
−13.4%
Rate of change
3-Period Avg
2.7x
Smoothed
Narrative signal
Pfizer Inc.’s price-to-sales ratio stands at 2.4x for Dec 2024. Year-over-year, the metric shifted by −0.37, translating into a −13.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-sales ratio shapes Pfizer Inc.'s story
As of Dec 2024, Pfizer Inc. reports price-to-sales ratio of 2.4x. Track price-to-sales multiples to contextualize revenue-driven valuation swings and peer comparisons.
When to use price-to-sales
P/S is helpful for companies with slim or volatile profits. It shows how rich investors value each dollar of revenue.
Compare against industry norms
High-growth software firms command higher P/S ratios than retailers. Stack the metric versus sector averages to read sentiment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.8%
Operating Margin
25.9%
Net Profit Margin
12.6%
Return on Equity
9.1%
Return on Assets
3.8%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Pfizer Inc. (PFE) FAQs
Answers tailored to Pfizer Inc.’s price-to-sales ratio profile using the latest Financial Modeling Prep data.
What is Pfizer Inc.'s current price-to-sales ratio?
As of Dec 2024, Pfizer Inc. reports price-to-sales ratio of 2.4x. This reading reflects the latest filings and price data for PFE.
How is Pfizer Inc.'s price-to-sales ratio trending year over year?
Year-over-year, the figure shifts by −0.37 (−13.4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PFE.
Why does price-to-sales ratio matter for Pfizer Inc.?
Price-to-sales compares market capitalization with revenue to assess valuation against top-line performance. For Pfizer Inc., operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Pfizer Inc.'s price-to-sales ratio above its recent average?
Pfizer Inc.'s rolling three-period average sits at 2.7x. Comparing the latest reading of 2.4x to that baseline highlights whether momentum is building or fading for PFE.
How frequently is Pfizer Inc.'s price-to-sales ratio refreshed?
Data for PFE was last refreshed on Dec 7, 2025, 2:50 AM and updates automatically every 24 hours, keeping your valuation inputs current.